Interventions of Interest: ICER’s Evidence Report Findings: Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year. Recommendations for fair access include ensuring that all biologic options be available for patients with severe […]
Interventions of Interest: Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently adequate to demonstrate a net health benefit of mavacamten added to background therapy. Using estimates from modeling of short-term benefits, mavacamten does show an overall benefit but would have to be priced below $15,000 per […]
Interventions of Interest: The independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a net health benefit when compared to conventional therapy alone. According to ICER’s health-benefit price benchmark, eculizumab would need to be priced between $13,200 – $19,400 to be considered cost-effective; efgartigimod’s price is not yet […]
Interventions of Interest: Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin. Atopic dermatitis is a subset of the broad classification of eczema. It is the most common skin disease in children, with 50% of patients experiencing onset […]
In June 2018, ICER announced its intention to assess the comparative clinical effectiveness and value of canakinumab (Novartis) for cardiovascular risk reduction in people with atherosclerosis. However, in October 2018, when the Food and Drug Administration declined to approve canakinumab’s expanded indication for atherosclerotic cardiovascular disease, ICER announced it would no longer proceed with its value assessment. […]
Interventions of Interest: Hysingla® ER (Hydrocodone, Purdue) Vantrela® (Hydrocodone , Teva) Arymo® ER ( Morphine, Egalet) Embeda® (Morphine + naltrexone, Pfizer) Morphabond® (Morphine extended release, Inspirion Delivery Technologies) OxyContin® TR (Oxycodone, Purdue) Xtampza®ER (Oxycodone, Collegium Pharmaceutical Inc) Targiniq® (Oxycodone + naloxone extended release, Purdue) Troxyca® ER (Oxycodone + naltrexone, Pfizer) RoxyBond® (Oxycodone, Inspirion Delivery Technologies) […]
Interventions of Interest: Rucaparib (Rubraca®, Clovis Oncology) Niraparib (Zejula®, Tesaro, Inc.) Olaparib (Lynparza®, AstraZeneca) ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer. During the public meeting the Midwest CEPAC voted on key questions related to the clinical effectiveness and value of the […]
Interventions of Interest: remdesivir (VEKLURY®) ICER released the results of its initial analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19. Working with external academic partners, ICER has developed ICER-COVID models comprising two alternative pricing paradigms for COVID-19 treatments: 1) “cost recovery” for the manufacturer, representing an […]
Interventions of Interest: voclosporin (Lupkynis™, Aurinia Pharmaceuticals) belimumab (Benlysta®, GlaxoSmithKline) ICER is assessing the comparative clinical effectiveness and value of voclosporin (Lupkynis™, Aurinia Pharmaceuticals) and belimumab (Benlysta®, GlaxoSmithKline) for the treatment of lupus nephritis. Voclosporin was approved for lupus nephritis in 2021, and belimumab is seeking a label expansion for the treatment of lupus nephritis. […]
Intervention of interest: Community health workers Disparities across racial and socioeconomic lines in the utilization of health care services and in patient outcomes continue to plague healthcare systems in the U.S. Policies to address health care disparities have varied, including steps to increase access to health insurance coverage at both the state and federal levels, […]